Sadahiro, Sotaro http://orcid.org/0000-0002-7800-3880
Sakamoto, Kazuhiro
Tsuchiya, Takashi
Takahashi, Takao
Ohge, Hiroki
Sato, Toshihiko
Kondo, Ken
Ogata, Yutaka
Baba, Hideo
Itabashi, Michio
Ikeda, Masataka
Hamada, Madoka
Maeda, Kiyoshi
Masuko, Hiroyuki
Takahashi, Keiichi
Sakamoto, Junichi
Kusano, Mitsuo
Hyodo, Ichinosuke
Taguri, Masataka
Morita, Satoshi
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 13 October 2021
Accepted: 31 January 2022
First Online: 15 February 2022
Declarations
:
: Written informed consent was obtained from all patients before enrollment. JFMC46-1201 (Japan Registry of Clinical Trials jRCTs031180155 [date of registration: 25/02/2019] and UMIN Clinical Trials Registry UMIN000007783 [date of registration: 18/04/2012]) was a multi-institutional study approved by the National Cancer Center Hospital East Certified Review Board (CRB3180009) and conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Kazuhiro Sakamoto received grants from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Pfizer Japan, Daiichi Sankyo, and Asahi Kasei Pharma, outside the submitted work. Takao Takahashi received research funding from Yakult Honsha and lecture fees from Takeda Pharmaceutical, Sanofi, and Taiho Pharmaceutical, outside the submitted work. Hideo Baba received personal fees from Eli Lilly Japan; grants and personal fees from Taiho Pharmaceutical and Ono Pharmaceutical; and grants from Merck Biopharma and MSD, outside the submitted work. Michio Itabashi received research funding from Astellas, Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, and Pfizer Japan, outside the submitted work. Masataka Ikeda received personal fees from Taiho Pharmaceutical, Daiichi Sankyo, and Pfizer, outside the submitted work. Junichi Sakamoto received personal fees from Chugai Pharmaceutical outside the submitted work. Ichinosuke Hyodo received grants and personal fees from Taiho Pharmaceutical during the conduct of the study; and grants and personal fees from Chugai Pharmaceutical, outside the submitted work. Satoshi Morita received personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Pfizer Japan, Taiho Pharmaceutical, and Ono Pharmaceutical, outside the submitted work. All remaining authors have no conflicts of interest to declare.